Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: Case report

Abstract

In the current report, we describe a patient with moderate nephritis and severe skin Henoch Schönlein purpura (HSP) who has been treated with rituximab. Complete and sustained skin and renal remission resulted from the treatment. Thus, further studies are required to confirm the efficacy of rituximab as first-line treatment in HSP, and it might be an interesting new therapeutic option. © 2009 The Author.